ClinicalTrials.gg
CompletedNCT00777348AERIAUpdated Feb 7, 2022

To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol

A Phase 2 interventional study of Combination DSCG and Reproterol in Asthma, Exercise-Induced, sponsored by MEDA Pharma GmbH & Co. KG. Completed at 7 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-07.

Sponsored by MEDA Pharma GmbH & Co. KG (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multicentre, randomised, double-blind, placebo-controlled, 4-way cross-over study. At each study visit a standardised treadmill test will be performed to provoke EIA. Before and after the challenge test pulmonary function variables (e.g. forced expiratory volume in one second (FEV1)) will be measured in order to assess the protective effect of the study medication.

Read the detailed description
  • Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).
  • Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus reproterol in comparison to the single component DSCG; to demonstrate superiority of the protective effect of each single component in comparison to placebo. In addition, the tolerability of medications will be documented.
02

Conditions studied

  • Asthma, Exercise-Induced
03

In context

Asthma, Exercise-Induced

52 studies on the registry are indexed under Asthma, Exercise-Induced; 3 are open to participants now.

This study's enrollment of 62 is above the median of 47 across 40 interventional studies indexed under Asthma, Exercise-Induced.

Browse Asthma, Exercise-Induced studies →

Lead sponsor

MEDA Pharma GmbH & Co. KG is the lead sponsor of 24 studies on the registry; none are open to participants now.

First submitted before MEDA Pharma GmbH & Co. KG became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male subjects aged 18 - 65 years
  • Exercise induced asthma with reversible airway obstruction: twice proven EIA defined as maximum decrease in against the baseline value of at least 20% (first test results can be obtained during the last 12 months)
  • Baseline FEV1 before challenge must be > or = 70% of the predicted FEV1

Exclusion criteria

Exclusion Criteria:

Safety concerns:

  • Subjects with to DSCG, reproterol, menthol, peppermint or other of the study medication
  • Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of defined as those which result in a low failure rate (i.e. \<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner
  • Subjects with an asthma exacerbation within 4 weeks prior to the study start. Asthma exacerbation defined as use of oral (systemic) glucocorticosteroids, unscheduled consultation of a medic due to asthma, hospitalisation, or additional treatment of asthma with antibiotics
  • Eosinophilic pneumonia
  • cardiovascular diseases (e.g. cardiac infarction, cardiac dysrhythmia, hypertrophic obstructive cardiomyopathy, coronary heart disease...)
  • Resting blood pressure over 140/90 mmHg
  • Diastolic blood pressure after treadmill-test over 120 mmHg
  • including phaeochromocytoma within the last 5 years
  • Severe hyperthyreosis, thyreotoxicosis, instable diabetes mellitus

Lack of suitability for the trial:

  • Subjects with seasonal asthma during their asthma season
  • Infectious disease of the upper airways within 2 weeks prior to the study and within 4 weeks prior to study in case of use of antibiotics
  • Relevant respiratory disorder other than asthma
  • Clinically significant renal, endocrine, haematological, hepatic, immunological, gastrointestinal, neurological, or psychiatric diseases
  • Any chronic disease which might influence absorption, metabolism, or excretion of the trial substances
  • Change of inhalative glucocorticosteroid dosage and / or antiasthmatic controller therapy within the last 4 weeks prior to or during the study
  • Concomitant systemic treatment with glucocorticosteroids
  • Concomitant treatment with any ß-antagonistic drug
  • Need of rescue medication within 15 min after challenge
  • Concomitant therapy with antidepressants or neuroleptics
  • Drug or alcohol abuse which would interfere with the subjects proper completion of the protocol assignment and mentally handicapped subjects
  • Smokers within the last 6 months or smoking history > 10 pack-years (a pack-year is 20 cigarettes per day for one year or equivalent)
  • Exposure to another agent within the last 4 weeks prior to this one or during this study
  • Non-cooperative subjects not able to understand the instructions for use of the devices

Administrative reasons:

  • Lack of ability or willingness to give
  • Lack of willingness to have personal study related data collected, archived or transmitted according to protocol
  • Anticipated non-availability for study visits / procedures
  • Personnel involved in the planning or conduct of the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    1

    DSCG + Reproterol

    Drug: Combination DSCG and Reproterol

  • Active comparator
    2

    DSCG

    Drug: Combination DSCG and Reproterol

  • Active comparator
    3

    Reproterol

    Drug: Combination DSCG and Reproterol

  • Placebo comparator
    4

    Placebo

    Drug: Combination DSCG and Reproterol

Interventions

  • DrugCombination DSCG and Reproterol

    1:

06

What researchers measure

Primary outcomes

  1. Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).

    Time frame: 5, 10, 15, 30 and 60 minutes after drug application

Secondary outcomes

  1. Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus reproterol in comparison to the single component DSCG; to demonstrate superiority of the protective effect of each single component in comparison to placebo.

    Time frame: 5, 10, 15, 30 and 60 minutes after drug application

07

Study locations

7 sites
  • Kurmittelhaus der Moderne
    Bad Reichenhall, D-83435, Germany
  • Asthma Center Buchenhoehe
    Berchtesgaden, D-83471, Germany
  • Practice Dr. T. Ginko
    Bonn, D-53119, Germany
  • Clinic St. Georg Leipzig, Robert Koch Clinic
    Leipzig, D-04207, Germany
  • Clinical Research Pneumology, III. Medical Clinic, University Clinic Mainz
    Mainz, D-55131, Germany
  • Practice Dr. W. Schürmann
    Marburg, D-35037, Germany
  • Institute for Pulmonary Research GmbH
    Wiesbaden, D-65187, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2008
First posted
Oct 22, 2008
Start
Nov 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Feb 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00777348
Collaborators
ClinResearch, GmbH, Sanofi
First posted
Oct 22, 2008
Start date
Nov 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Feb 7, 2022

Study contacts

Roland Buhl, MD, Prof.
principal investigator · Clinical Research Pneumology, III. Medical Clinic, University Clinic Mainz

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion